These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. How serious is the bronchospasm induced by rapacuronium? Naguib M Anesthesiology; 2001 May; 94(5):924-5. PubMed ID: 11388547 [No Abstract] [Full Text] [Related]
5. Severe bronchospasm and desaturation in a child associated with rapacuronium. Kron SS Anesthesiology; 2001 May; 94(5):923-4. PubMed ID: 11388546 [No Abstract] [Full Text] [Related]
6. Bronchospasm after rapacuronium in infants and children. Meakin GH; Pronske EH; Lerman J; Orr R; Joffe D; Savaree AM; Lynn AM Anesthesiology; 2001 May; 94(5):926-7. PubMed ID: 11388548 [No Abstract] [Full Text] [Related]
8. Rapacuronium: why did it fail as a replacement for succinylcholine? White PF Br J Anaesth; 2002 Feb; 88(2):163-5. PubMed ID: 11878650 [No Abstract] [Full Text] [Related]
9. Rapacuronium: premarket drug evaluation can be very effective for the identification of drug risks. Lim R Anesth Analg; 2003 Feb; 96(2):631-2. PubMed ID: 12538231 [No Abstract] [Full Text] [Related]
10. Rapacuronium and the risk of bronchospasm in pediatric patients. Rajchert DM; Pasquariello CA; Watcha MF; Schreiner MS Anesth Analg; 2002 Mar; 94(3):488-93; table of contents. PubMed ID: 11867363 [TBL] [Abstract][Full Text] [Related]
11. Which formulation of propofol was used? Matsumura JS Anesthesiology; 2002 Jun; 96(6):1529; author reply 1529-30. PubMed ID: 12170076 [No Abstract] [Full Text] [Related]
12. Further comments on the withdrawal of rapacuronium. Sosis MB Anesth Analg; 2002 Oct; 95(4):1126-7. PubMed ID: 12351320 [No Abstract] [Full Text] [Related]
13. Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle. Jooste E; Zhang Y; Emala CW Anesthesiology; 2005 Jan; 102(1):117-24. PubMed ID: 15618795 [TBL] [Abstract][Full Text] [Related]
14. The effect on lung mechanics in anesthetized children with rapacuronium: a comparative study with mivacurium. Fine GF; Motoyama EK; Brandom BW; Fertal KM; Mutich R; Davis PJ Anesth Analg; 2002 Jul; 95(1):56-61, table of contents. PubMed ID: 12088943 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent. Larijani GE; Zafeiridis A; Goldberg ME Pharmacotherapy; 1999 Oct; 19(10):1118-22. PubMed ID: 10512060 [TBL] [Abstract][Full Text] [Related]
16. Rapacuronium (Org 9487): do we have a replacement for succinylcholine? Goulden MR; Hunter JM Br J Anaesth; 1999 Apr; 82(4):489-92. PubMed ID: 10472209 [No Abstract] [Full Text] [Related]
18. Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors. Jakubík J; Randáková A; El-Fakahany EE; Dolezal V BMC Pharmacol; 2009 Dec; 9():15. PubMed ID: 20038295 [TBL] [Abstract][Full Text] [Related]
19. Rapacuronium bromide: a review of its use in anaesthetic practice. Onrust SV; Foster RH Drugs; 1999 Nov; 58(5):887-918. PubMed ID: 10595867 [TBL] [Abstract][Full Text] [Related]
20. Newer neuromuscular blocking agents: how do they compare with established agents? Sparr HJ; Beaufort TM; Fuchs-Buder T Drugs; 2001; 61(7):919-42. PubMed ID: 11434449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]